Abstract：
OBJECTIVE: The present study aims to review the existing literature to identify pathophysiological proteins in obesity by conducting a systematic review of proteomics studies. Proteomics may reveal the mechanisms of obesity development and clarify the links between obesity and related diseases, improving our comprehension of obesity and its clinical implications.
RESULTS: Most of the molecular events implicated in obesity development remain incomplete. Proteomics stands as a powerful tool for elucidating the intricate interactions among proteins in the context of obesity. This methodology has the potential to identify proteins involved in pathological processes and to evaluate changes in protein abundance during obesity development, contributing to the identification of early disease predisposition, monitoring the effectiveness of interventions and improving disease management overall. Despite many non-targeted proteomic studies exploring obesity, a comprehensive and up-to-date systematic review of the molecular events implicated in obesity development is lacking. The lack of such a review presents a significant challenge for researchers trying to interpret the existing literature. This systematic review was conducted following the PRISMA guidelines and included sixteen human proteomic studies, each of which delineated proteins exhibiting significant alterations in obesity. A total of 41 proteins were reported to be altered in obesity by at least two or more studies. These proteins were involved in metabolic pathways, oxidative stress responses, inflammatory processes, protein folding, coagulation, as well as structure/cytoskeleton. Many of the identified proteomic biomarkers of obesity have also been reported to be dysregulated in obesity-related disease. Among them, seven proteins, which belong to metabolic pathways (aldehyde dehydrogenase and apolipoprotein A1), the chaperone family (albumin, heat shock protein beta 1, protein disulfide-isomerase A3) and oxidative stress and inflammation proteins (catalase and complement C3), could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, contributing to personalized medicine in the field of obesity. Our systematic review in proteomics represents a substantial step forward in unravelling the complexities of protein alterations associated with obesity. It provides valuable insights into the pathophysiological mechanisms underlying obesity, thereby opening avenues for the discovery of potential biomarkers and the development of personalized medicine in obesity.
RESULTS: Most of the molecular events implicated in obesity development remain incomplete. Proteomics stands as a powerful tool for elucidating the intricate interactions among proteins in the context of obesity. This methodology has the potential to identify proteins involved in pathological processes and to evaluate changes in protein abundance during obesity development, contributing to the identification of early disease predisposition, monitoring the effectiveness of interventions and improving disease management overall. Despite many non-targeted proteomic studies exploring obesity, a comprehensive and up-to-date systematic review of the molecular events implicated in obesity development is lacking. The lack of such a review presents a significant challenge for researchers trying to interpret the existing literature. This systematic review was conducted following the PRISMA guidelines and included sixteen human proteomic studies, each of which delineated proteins exhibiting significant alterations in obesity. A total of 41 proteins were reported to be altered in obesity by at least two or more studies. These proteins were involved in metabolic pathways, oxidative stress responses, inflammatory processes, protein folding, coagulation, as well as structure/cytoskeleton. Many of the identified proteomic biomarkers of obesity have also been reported to be dysregulated in obesity-related disease. Among them, seven proteins, which belong to metabolic pathways (aldehyde dehydrogenase and apolipoprotein A1), the chaperone family (albumin, heat shock protein beta 1, protein disulfide-isomerase A3) and oxidative stress and inflammation proteins (catalase and complement C3), could potentially serve as biomarkers for the progression of obesity and the development of comorbidities, contributing to personalized medicine in the field of obesity. Our systematic review in proteomics represents a substantial step forward in unravelling the complexities of protein alterations associated with obesity. It provides valuable insights into the pathophysiological mechanisms underlying obesity, thereby opening avenues for the discovery of potential biomarkers and the development of personalized medicine in obesity.
摘要：
目的：本研究旨在通过对蛋白质组学研究的系统综述，对现有文献进行综述，以鉴定肥胖的病理生理蛋白。蛋白质组学可以揭示肥胖发生发展的机制，阐明肥胖与相关疾病之间的联系。提高我们对肥胖的理解及其临床意义。
结果：大多数与肥胖发展有关的分子事件仍然不完整。蛋白质组学是阐明肥胖背景下蛋白质之间复杂相互作用的强大工具。这种方法有可能鉴定参与病理过程的蛋白质，并评估肥胖发展过程中蛋白质丰度的变化。有助于识别早期疾病易感性，监测干预措施的有效性，全面改善疾病管理。尽管许多非靶向蛋白质组学研究探索肥胖，目前尚缺乏对与肥胖发生有关的分子事件进行全面和最新的系统评价.缺乏这样的评论对试图解释现有文献的研究人员提出了重大挑战。这项系统评价是根据PRISMA指南进行的，包括16项人类蛋白质组学研究。其中每一个描绘了在肥胖中表现出显著变化的蛋白质。据报道，至少有两项或更多项研究表明，肥胖中总共有41种蛋白质发生了改变。这些蛋白质参与了代谢途径，氧化应激反应，炎症过程，蛋白质折叠，凝血,以及结构/细胞骨架。据报道，许多已鉴定的肥胖蛋白质组生物标志物在肥胖相关疾病中失调。其中,七种蛋白质,属于代谢途径（醛脱氢酶和载脂蛋白A1），伴侣家族(白蛋白，热休克蛋白β1，蛋白质二硫键异构酶A3）和氧化应激和炎症蛋白（过氧化氢酶和补体C3），可能作为肥胖进展和合并症发展的生物标志物，有助于肥胖领域的个性化医疗。我们在蛋白质组学方面的系统综述代表了在揭示与肥胖相关的蛋白质改变的复杂性方面迈出的重要一步。它为肥胖的病理生理机制提供了有价值的见解，从而为发现潜在的生物标志物和发展肥胖个性化医疗开辟了道路。
结果：大多数与肥胖发展有关的分子事件仍然不完整。蛋白质组学是阐明肥胖背景下蛋白质之间复杂相互作用的强大工具。这种方法有可能鉴定参与病理过程的蛋白质，并评估肥胖发展过程中蛋白质丰度的变化。有助于识别早期疾病易感性，监测干预措施的有效性，全面改善疾病管理。尽管许多非靶向蛋白质组学研究探索肥胖，目前尚缺乏对与肥胖发生有关的分子事件进行全面和最新的系统评价.缺乏这样的评论对试图解释现有文献的研究人员提出了重大挑战。这项系统评价是根据PRISMA指南进行的，包括16项人类蛋白质组学研究。其中每一个描绘了在肥胖中表现出显著变化的蛋白质。据报道，至少有两项或更多项研究表明，肥胖中总共有41种蛋白质发生了改变。这些蛋白质参与了代谢途径，氧化应激反应，炎症过程，蛋白质折叠，凝血,以及结构/细胞骨架。据报道，许多已鉴定的肥胖蛋白质组生物标志物在肥胖相关疾病中失调。其中,七种蛋白质,属于代谢途径（醛脱氢酶和载脂蛋白A1），伴侣家族(白蛋白，热休克蛋白β1，蛋白质二硫键异构酶A3）和氧化应激和炎症蛋白（过氧化氢酶和补体C3），可能作为肥胖进展和合并症发展的生物标志物，有助于肥胖领域的个性化医疗。我们在蛋白质组学方面的系统综述代表了在揭示与肥胖相关的蛋白质改变的复杂性方面迈出的重要一步。它为肥胖的病理生理机制提供了有价值的见解，从而为发现潜在的生物标志物和发展肥胖个性化医疗开辟了道路。
